+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Cancer/Tumor Profiling Market 2019-2025

  • PDF Icon

    Report

  • October 2019
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 4871635
UP TO OFF until Dec 31st 2022
Global Cancer/Tumor Profiling Market Size, Share & Trends Analysis Report by Technology (Immunoassays, In Situ Hybridization, Sequencing Techniques, Mass Spectrometry, and Others), by Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Melanoma Cancer, and Others), and by End-User (Clinics and Hospitals, and Research Centers) and Forecast 2019-2025.

The increasing demand for cancer/tumor profiling methods by the oncologists to diagnose and treat cancer is projected to drive global market. Additionally, the growing adoption of cancer biomarkers for tumor profiling along with the rising incidence of cancer across the globe is another factor to fuel the growth of the global market. Furthermore, the growing utility of the next-generation sequencing technique is anticipated to fuel the growth of the market. However, hefty investments for the development of biomarkers and lack of skilled professionals or oncologists specific to tumor profiling are likely to hamper market growth.

The cancer/tumor profiling market is segmented on the basis of technology, cancer type, and end-user. Based on technology, the market is segmented into immunoassays, in situ hybridization, sequencing techniques, mass spectrometry, and others. Among these technologies, the immunoassays are projected to hold a significant market share, owing to their high utilization as a gold standard for the conduction of large-scale tumor profiling.

Global cancer/tumor profiling market is further segmented on the basis of geography, including North America, Europe, Asia-Pacific, and Rest of the World. North America held a significant share in the global market in 2018. This is due to the well-developed healthcare infrastructure and rapid adoption of advanced technologies by the pharmaceutical companies. Asia-Pacific is anticipated to witness a considerable growth in the global cancer/tumor profiling market during the forecast period. This is owing to the increasing requirement of cancer/ tumor profiling kits due to the rising number of cancer cases in the region.

Key players of cancer/tumor profiling market include QIAGEN N.V., Genomic Health, Inc., Sysmex Corp., Illumina Inc., and Thermo Fisher Scientific Inc., and so on. In order to retain in the competitive market, these players adopt different growth strategies such as merger and acquisition, partnership, product launch, and collaboration to stay competitive in the market. For instance, in September 2017, INDIVUMED entered into a partnership with Helomics to unlock the power of cancer biospecimens for drug discovery and development.

Research Methodology

The market study of global cancer/tumor profiling market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research organizations, investment companies, government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:
1. Global Cancer/Tumor Profiling Market Research and Analysis by Technology
2. Global Cancer/Tumor Profiling Market Research and Analysis by Cancer Type
3. Global Cancer/Tumor Profiling Market Research and Analysis by End-User

The Report Covers
  • Comprehensive research methodology of global cancer/tumor profiling market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting global cancer/tumor profiling market.
  • Insights about market determinants which are stimulating global cancer/tumor profiling market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. F. Hoffmann-La Roche Ltd.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Genomic Health, Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Sysmex Corp.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. QIAGEN N.V.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Illumina, Inc.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Cancer/Tumor Profiling Market by Technology
5.1.1. Immunoassay
5.1.2. In Situ Hybridization
5.1.3. Sequencing techniques
5.1.4. Mass spectrometry
5.1.5. Others (Microarray)
5.2. Global Cancer/Tumor Profiling Market by Cancer Type
5.2.1. Lung cancer
5.2.2. Breast cancer
5.2.3. Prostate cancer
5.2.4. Melanoma cancer
5.2.5. Others (colorectal cancer)
5.3. Global Cancer/Tumor Profiling Market by End-User
5.3.1. Clinics and Hospitals
5.3.2. Research Centers
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Agilent Technologies, Inc.
7.2. Almac Group Ltd.
7.3. Biodesix, Inc.
7.4. Biospherex LLC
7.5. Cepheid
7.6. Cernostics, Inc.
7.7. F. Hoffmann-La Roche Ltd.
7.8. General Electric Co.
7.9. Genomic Health, Inc.
7.10. Illumina, Inc.
7.11. Lunaphore Technologies S.A.
7.12. Metabiomics Corp.
7.13. Myriad Genetics, Inc.
7.14. Novartis International AG
7.15. OPKO Health, Inc.
7.16. PerkinElmer Inc.
7.17. Personalis, Inc.
7.18. QIAGEN N.V.
7.19. Sysmex Corp.
7.20. Thermo Fisher Scientific Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Agilent Technologies, Inc.
  • Almac Group Ltd.
  • Biodesix, Inc.
  • Biospherex LLC
  • Cepheid
  • Cernostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • General Electric Co.
  • Genomic Health, Inc.
  • Illumina, Inc.
  • Lunaphore Technologies S.A.
  • Metabiomics Corp.
  • Myriad Genetics, Inc.
  • Novartis International AG
  • OPKO Health, Inc.
  • PerkinElmer Inc.
  • Personalis, Inc.
  • QIAGEN N.V.
  • Sysmex Corp.
  • Thermo Fisher Scientific Inc.